Valuation: Theracryf Plc

Market Cap 6.39M 5.57M 5.25M 4.78M 8.96M 613M 8.98M 62.88M 24.24M 312M 24.02M 23.48M 1.01B P/E 2026 *
-1.17x
P/E 2027 * -1.56x
Enterprise Value 4.23M 3.69M 3.48M 3.17M 5.94M 406M 5.94M 41.64M 16.05M 207M 15.9M 15.55M 667M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
64.1%
Yield 2026 *
-
Yield 2027 * -
1 week-5.41%
Current month-7.89%
1 month-7.89%
3 months-25.53%
6 months-14.63%
Current year-12.50%
1 week 0.16
Extreme 0.162
0.2
1 month 0.16
Extreme 0.162
0.2
Current year 0.16
Extreme 0.16
0.27
1 year 0.16
Extreme 0.16
0.27
3 years 0.16
Extreme 0.16
2.3
5 years 0.16
Extreme 0.16
7.8
10 years 0.16
Extreme 0.16
30.5
Manager TitleAgeSince
Chief Executive Officer 64 30/09/2020
Director of Finance/CFO - 04/09/2023
Chief Tech/Sci/R&D Officer - 30/04/2021
Director TitleAgeSince
Director/Board Member - 13/10/2015
Director/Board Member 64 30/09/2020
Director/Board Member - 31/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25 Others

Director

422,727,272 19.8499%
04/03/25 Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.41%-30.00%-92.55% 6.4M
+4.98%+5.73%+54.45%+113.83% 70.88B
-0.39%+0.02%+38.84%+83.28% 62.49B
0.00%+7.68%+32.24%+24.27% 26.34B
+0.83%-3.43%-16.41%+359.38% 26.21B
+2.02%-0.87%+1.85%-7.92% 24.13B
0.00%+6.81%+25.03%-11.44% 20.72B
-2.54%-3.36%+149.64%+324.48% 15.69B
-1.95%+1.80%+42.69%+165.15% 14.46B
-5.32%-8.25%-10.53%+823.50% 14.24B
Average -0.24%+0.19%+28.78%+178.20% 27.52B
Weighted average by Cap. +0.93%+2.17%+36.65%+153.02%

Financials

2026 *2027 *
Net sales - -
Net income -3.38M -2.95M -2.77M -2.53M -4.74M -324M -4.74M -33.23M -12.81M -165M -12.69M -12.41M -532M -3.46M -3.02M -2.84M -2.59M -4.85M -331M -4.86M -34.01M -13.11M -169M -12.99M -12.7M -545M
Net Debt -2.16M -1.88M -1.77M -1.62M -3.03M -207M -3.03M -21.24M -8.19M -105M -8.11M -7.93M -340M -704K -614K -578K -526K -987K -67.44M -988K -6.92M -2.67M -34.35M -2.64M -2.59M -111M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
21/09/26 GBX 0.1750 0.00% 3,778
18/09/26 GBX 0.1750 -5.41% 5,733,950
17/09/26 GBX 0.1850 0.00% 305,295
16/09/26 GBX 0.1850 0.00% 79,200
15/09/26 GBX 0.1850 0.00% 169,426
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002340USD
Average target price
0.0162USD
Spread / Average Target
+593.58%

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!